Novel Drug Shows Promise in Multiple Sclerosis

(MedPage Today) -- MILAN -- Treatment with investigational frexalimab, a novel CD40 ligand (CD40L) inhibitor, led to sustained reduction of MRI disease activity in relapsing multiple sclerosis (MS) at 6 months, follow-up data from a phase II...
Source: MedPage Today Neurology - Category: Neurology Source Type: news